IND Program CCTG

The Investigational New Drug Program of the Canadian Cancer Trials Group

[IND Program CCTG @INDProgramCCTG]

Congratulations @Philippe_Bedard on the ESMO-TAT Honorary Award 2025 @CDNCancerTrials

[IND Program CCTG @INDProgramCCTG]

Academic consortia around the world https://t.co/38hcTADHCq

[IND Program CCTG @INDProgramCCTG]

ENA 2024 is in Barcelona from 23-25 October! 🌟 Don’t miss out on the top-notch sessions and dynamic networking opportunities. Register today #ENASymp24 https://t.co/RZeOKIh0ws

[IND Program CCTG @INDProgramCCTG]

@peters_solange @ChristinaBYap @danieltanmd @GPentheroudakis @FAndreMD @curijoey @DrIgMelero @PaoloNuciforo @brainstrust @DMBranco

[IND Program CCTG @INDProgramCCTG]

MDICT 2024 recommendations for neoadjuvant early clinical trials now published. Led by ESMO-TAT chairs @lillian_siu @ElenaGarralda @AnastasiosStat2 and MDICT’24 team supported by @myESMO

https://t.co/RZdCpG0iWG

[IND Program CCTG @INDProgramCCTG]

MDICT 2024 recommendations for neoadjuvant early clinical trials now published. Led by ESMO-TAT chairs @lillian_siu @ElenaGarralda @AnastasiosStat2 and MDICT’24 team supported by @myESMO

https://t.co/RZdCpG0iWG

[ASCO @ASCO]

🎙️@PBarataMD of @UHhospitals and @lillian_siu of @pmcancercentre discuss recent state-of-the-art advancements in cancer vaccine development on the latest episode of the #ASCODailyNews Podcast: https://t.co/06CrLnOyAq

[Friends of Cancer Research @CancerResrch]

The @FDA's recent draft guidance on #DiversityActionPlans for clinical trials is an important step towards more inclusive and representative trials. Friends CEO Jeff Allen recently spoke to @RAPSorg about this guidance and its importance. https://t.co/Pqu7C0usuQ

[AACR @AACR]

Register by September 4 to get the lowest available rates for the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (October 23-25, Barcelona, Spain), chaired by @VriesElisabeth, @TimGreten, and Timothy A. Yap.
https://t.co/mvxzXiTSmH
#ENASymp24

[Queen's Health Sciences @QueensUHealth]

Nerve cells were considered bystanders in the spread of #cancer. Dr. Sebastien Talbot has revealed that certain nerve cells are key to tumour survival. Learn more about his research supported by @azrielifdn & @BrainCanada: https://t.co/M5k3WUBnzh @queensuResearch @QueensuSCRI

[AACR Foundation @AACRFoundation]

Did you know smoking tobacco increases the risk of developing 18 types of cancers? Learn about ways to reduce the burden of cancer in the @AACR #CancerProgressReport. https://t.co/WSsaccSgZR

[IASLC @IASLC]

Explore the forefront of thoracic oncology at #WCLC24! With 6,000+ delegates from over 100 countries, it is a must-attend event for professionals in the field of lung and other thoracic cancers. Register by July 29 at https://t.co/TPo86SYfE1

[CCTG @CDNCancerTrials]

July is #SarcomaAwarenessMonth. Join us in raising awareness and supporting those affected by the battle against Sarcoma. #CCTG is inspired by the strength and resilience of all patients and families. We are committed to advancing research and helping improve lives.

[Research at Canadian Cancer Society @CCSResearch]

Congratulations to former @cancersociety board member Dr Tony Fields, who served as president of the National Cancer Institute of Canada (CCS’s research arm before integration). A well-deserved recognition for an outstanding career and leadership!

[Dr. Anthony Letai @NCIDirector]

🌟Attention students and trainees looking for a postdoc experience at @theNCI: The NCI Cancer Prevention Fellowship Program is accepting applications through Aug 1!

Don’t miss this opportunity! https://t.co/djrLHaB3Ys

[Genentech @genentech]

#Breaking: Today, we provided an update on the Phase II/III trial evaluating our investigational anti-#TIGIT cancer immunotherapy in advanced non-squamous NSCLC. Learn more: https://t.co/p3826yFEvi

[Giannis Mountzios @g_mountzios]

⚠️ From press release on Skyscraper -06: Tira+Atezo +chemo INCREASED by 33% the risk of DEATH compared to Pembro +chemo 🤦🏻

Could ICI combos exert detrimental effect? More is NOT always better in IO and some ICI combos may have hetero-neutralizing impact on microenvironmental immune activation

IMO we should abandon “chemo+Pembro+ “another ICI” trials in unselected populations and try to define molecularly selected subsets( co-mutations?) of pts who require combinatorial approaches

#some #LCSM @OncoAlert @OncBrothers

[MRC-NIHR Trials Methodology Research Partnership @MRCNIHRTMRP]

Come and join us! We are recruiting a fully funded PhD student to our @MRCTMRPDTP with @ChristinaBYap at ICR. Please share widely. Closing date 15 August. For more information see https://t.co/mK20m6jyB1

[Queen's University Global @QueensUGlobal]

Great news for Horizon Europe and Canada, this will lead to a wealth of opportunities for collaborative research! 🇪🇺

[Stephen V Liu, MD @StephenVLiu]

Retrospective look at impact of durvalumab on pneumonitis after chemoradiation for NSCLC @ClinicalLung. With durva, 57% G1 pneumonitis, 38% G2, 5% G3. Steroid course 17w with durva and 7w without. Pneumonitis relapse 23% with durvalumab, 7% without.

https://t.co/fSAgS4fkxW

[Canadian Cancer Society @cancersociety]

Exercise and wellness have lots of advantages for people with cancer – before, during and after treatment.

The Canadian Cancer Society is proud to fund a wide range of research projects focused on encouraging exercise to improve the well-being of people living with or beyond cancer.

To read about the 5 projects we’re excited to highlight and the teams that are making this all happen, visit this link today: https://t.co/6b8k7wOWTe